Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an ...
Healio1d
Nemluvio approved in EU, UK, Switzerland for atopic dermatitis, prurigo nodularis
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
Biotech Firm Acelyrin Inc. to Merge with Alumis Inc. in $320M Deal
Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...